Related Experiment Video

Updated: May 13, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

An update on the clinical development of drugs to disable tumor vasculature

Dietmar W Siemann1, David J Chaplin

  • 1Professor and Associate Chair for Research, University of Florida, Department of Radiation Oncology, Shands Cancer Center, 2000 SW Archer Road, Gainesville, Fl 32610, USA +1 352 265 0287 ; +1 352 265 0759 ; siemadw@ufl.edu.

Expert Opinion on Drug Discovery
|March 15, 2013
PubMed

Insights

New cancer therapies target tumor vasculature, disrupting nutrient supply. This review explores vascular disrupting agents, a promising strategy beyond traditional tumor cell kill methods.

Area of Science:

  • Oncology
  • Vascular Biology
  • Drug Development

Background:

  • Traditional cancer treatments focus on direct tumor cell killing.
  • Emerging strategies target the tumor's blood supply (vasculature).
  • Tumor vasculature is crucial for providing nutrients and oxygen.

Purpose of the Study:

  • To review the latest advancements in vascular disrupting therapies for cancer.
  • To highlight potential targets and investigational drugs in this field.
  • To provide an overview of current clinical development.

Main Methods:

  • Literature review of vascular disrupting therapies.
  • Analysis of identified targets and investigational drugs.
  • Summary of ongoing clinical trials.

Main Results:

  • Identification of multiple targets within tumor vasculature.
  • Development of numerous investigational drugs for vascular disruption.
  • Progression of many agents into clinical trials.

Conclusions:

  • Vascular disrupting therapies represent a significant shift in cancer treatment strategies.
  • Targeting tumor vasculature offers a novel approach to impairing tumor growth.
  • Ongoing research and clinical development show promise for these novel therapies.

More Related Videos

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...